Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"We are very pleased to see this important program achieve success in a Phase 3 pivotal clinical trial," said Gregory Frost, Ph.D., Halozyme's president and CEO. "The convenience of subcutaneous administration may provide another option for women living with early breast cancer."

No new safety signals were observed and adverse events were overall consistent with Herceptin IV. Data from the trial will be submitted for presentation at an upcoming medical meeting and will support a marketing application to regulatory authorities in the European Union in 2012.

Roche has additional ongoing trials of a subcutaneous formulation of MabThera® (rituximab), using Enhanze™ Technology in pat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- ResMed Inc. (NYSE: RMD ) today announced that ... June 30, 2015 results on Thursday, July 30, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/2/2015)... 2, 2015 Releases of the ... Aedes aegypti , , reduced the dengue mosquito ... by 95%, well below the modelled threshold ... , The journal PLOS Neglected Tropical Diseases ... genetically engineered mosquitoes. The results showed that in Juazeiro ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has ... Imaging and by Application - Forecast to 2020" report to ... to reach $13.1 Billion in 2020 from an estimated $7.1 Billion ... market is dominated by North America , followed ... and Rest of the World (RoW). The cancer diagnostics market in ...
Breaking Medicine Technology:ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
... 17, 2011 Attorneys representing a group of U.S. citizens ... the drug thalidomide have filed a lawsuit in federal court ... show the drug was widely distributed in the United States. ... to respond to a number of Freedom of Information Act ...
... WASHINGTON, Nov. 17, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... employers, unions, and state employee plans, according to new ... Care Management Association (PCMA).   The use of these ...
Cached Medicine Technology:Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 2Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 3Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $617 Million in Wisconsin 2
(Date:7/4/2015)... ... 2015 , ... When a hacker gains access to someone’s email account, it can lead to ... July 1st, the FTC issued a scam alert about a social engineering scam ... a password reset instigated by the hacker. All they have to do is click ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... Friend opened registration for a new SEO training system called "Page One ... for organic traffic generation has received glowing reviews from several well-known marketers. HonestyFirstReviews.com's ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... providers, has been retained to lead a national president recruitment for ... in the healthcare industry, B. E. Smith has recently placed more than 1,000 ...
(Date:7/3/2015)... ... 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce the ... Center website. Just as the previous version did, the new website will serve as ... and ovarian cancer warning information. The site is routinely updated with news articles on ...
(Date:7/3/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and expose popular lies regarding proper relationships according to the bible. , ... the core of the subject by explaining why certain types of sexual relationships are ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... be only a dash and sprinkel away: Researchers with ... in addition to making food tastier, are an abundant ... when supplementing a balanced diet.Herbs have higher antioxidant activity ... researchers say. Their findings appear in the Journal of ...
... Sickle cell disease, sometimes called sickle cell anemia, is ... become sickle-shaped, which makes it difficult// for the cells ... the body's tissues. Young sickle cell patients who are ... from supplemental zinc, a mineral essential for growth and ...
... researchers at the Israel Deaconess Medical Center in Dallas, there ... impact that weight loss can make in decreasing the complications ... the first long-term study on how weight loss affects the ... cent of the population now classified as overweight, and diabetes ...
... sniff out men whose body odour is similar to that ... smells similar to a woman's father is likely to have ... humans produce are called pheromones. They are influenced to a ... system called the Major Histocompatibility Complex (MHC) . ,50 ...
... smoking accelerates the risk of heart disease, but now researchers ... development of a heart attack.This is because each cigarette appears ... the cardiovascular system.// ,In a study of heart attack ... within six hours of developing symptoms had bigger blood clots ...
... cell swallows a small capsule-shaped bacteria. The immune cells which ... way they should in space travellers and it could be ... Johnson Space Center (JSC) have been studying how immune cells ... health effects of space on astronauts.// ,It has been ...
Cached Medicine News:Health News:Herbs: rich soure of antioxidants 2Health News:Immune cells halt round in space 2
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
... securely in place. Soft strap features an ... Soft compliant foam laminate with elastic adjustment ... edema while still providing a snug fit. ... helps prevent sliding and patient irritation, and ...
... Percutaneous Dilation Tracheostomy Kits allow ... tracheostomy tube using the widely ... of a single-stage curved dilator. ... without the Portex® Blue Line ...
... Self-contained kits provide convenience and cost control. ... care trays offer a variety of wound ... management of the tracheostomized patient. , ... and trays with disposable inner cannula for ...
Medicine Products: